For clinicians
Cross-assay MRD/ctDNA limit-of-detection table
Last updated November 17, 2026
Prepared 2026-11-17 (CT). Every figure was checked live on 2026-11-17 at the URL given.
1 ppm = 0.0001% (VAF or tumor fraction). ppm = % x 10,000. Molecules/mL, copies/uL and cell counts cannot be converted without input-DNA data.
Vendor and study figures are not head-to-head. Definitions differ: LOD95 (lowest level detected in 95% of replicates) vs detection threshold vs 'observed' detection vs LOQ or reporting floor; ppm vs VAF vs methylation-based tumor fraction vs molecules/mL; LOD depends on input DNA (ng of cfDNA) and number of variants tracked; most figures come from contrived (cell-line) dilutions and many are vendor-reported. Lower LOD does not by itself mean better clinical sensitivity or outcomes. Rows are grouped by approach; order within a group carries no meaning and is not a ranking.
Tumor-informed
| Assay | Vendor | Approach / method | LOD as stated | ppm | VAF or TF % | Conversion | LOQ / reporting floor | Variants / input | Evidence | Medicare (A58454, R20) | Source(s), checked |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NeXT Personal | Personalis; U.S. commercialization with Tempus | tumor-informed; Tumor + matched-normal WGS, personalized panel sequenced in plasma | Detection threshold (mean): 1.67 PPM | 1.67 | 0.000167 | 1.67 ppm x 0.0001 = 0.000167% | Linearity 0.8 to 300,000 PPM (not stated as an LOQ) | Up to ~1,800 somatic variants | peer-reviewed analytical validation (all authors Personalis employees) | Named in A58454: neoadjuvant breast; recurrence/relapse with personal history of cancer for NSCLC and advanced breast; ICI-response monitoring in stage IV solid tumors. A58454 |
|
| NeXT Personal | LOD95: 3.45 PPM | 3.45 | 0.000345 | 3.45 ppm x 0.0001 = 0.000345% | |||||||
| Signatera (exome-based, bespoke multiplex PCR) | Natera | tumor-informed; Tumor + matched-normal WES, 16 clonal variants by multiplex PCR, ultra-deep sequencing | Limit of detection: not independently published | not independently published | not independently published | not independently published | not independently published | not independently published | not independently published | Named in A58454: advanced colorectal; muscle-invasive bladder and ovarian; neoadjuvant breast; NSCLC and advanced breast recurrence; ICI-response monitoring (advanced solid tumors). A58454 | |
| Signatera Genome | Natera | tumor-informed; WGS-based design | Limit of detection: not independently published | not independently published | not independently published | not independently published | Not published | not independently published | not independently published | Not named separately in A58454 (Signatera listings do not specify Genome). A58454 | |
| RaDaR ST | NeoGenomics | tumor-informed; Tumor sequencing to select variants; patient-specific amplicon panel | Limit of detection: not independently published | not independently published | not independently published | not independently published | not independently published | Up to 48 tumor-specific variants (Gale 2022, original RaDaR) | variant count is peer-reviewed; the limit of detection is not independently published | Named in A58454: HPV-negative HNSCC; advanced breast recurrence; ICI-response monitoring in stage IV solid tumors (added in R20, effective 4/9/2026). A58454 |
|
| Haystack MRD | Quest Diagnostics (Haystack Oncology) | tumor-informed; Tracks patient-specific somatic mutations with duplex error correction | LOD95 (peer-reviewed): 0.063 mean ctDNA molecules/mL | not convertible | not convertible | Not convertible: molecules per mL of plasma depend on total cfDNA per mL | Analytical measurement range 0.25 to 1000 mean ctDNA molecules/mL | Not stated in abstract | peer-reviewed analytical + clinical validation (Quest/Haystack authors) | Not named in A58454. A58454 |
|
| Oncodetect (next-generation, WGS + MAESTRO) | Exact Sciences | tumor-informed; WGS-based design with MAESTRO enrichment | Limit of detection: not independently published | not independently published | not independently published | not independently published | Not published | not independently published | not independently published | Named in A58454 as Oncodetect for advanced colorectal cancer. Whether that listing covers a later version is not stated in the Medicare article. A58454 | |
| Pathlight | SAGA Diagnostics | tumor-informed; Tumor WGS to find structural variants; personalized multiplex digital PCR | LoD95 at 70 ng cfDNA input: 0.00052% (paper rounds to 5 ppm) | 5.2 | 0.00052 | 0.00052% / 0.0001 = 5.2 ppm | Not published | Up to 16 SVs per tumor (median 14, range 4-16 in the study); LoD95 at 70 ng and 300 ng input | peer-reviewed (cell-line dilution, probit) | Named in A58454: advanced breast recurrence/relapse with personal history of cancer. A58454 |
|
| Pathlight | LoD95 at 300 ng input: 0.00011% (1.1 ppm) | 1.1 | 0.00011 | 0.00011% / 0.0001 = 1.1 ppm | |||||||
| Precise MRD | Myriad Genetics | tumor-informed; WGS-based personalized panel | Limit of detection: not independently published | not independently published | not independently published | not independently published | Not published | not independently published | not independently published | Not named in A58454. A58454 | |
| Invitae Personalized Cancer Monitoring (PCM) | Invitae (select assets acquired by Labcorp, 2024) | tumor-informed; Tumor + germline WES; patient-specific panel | LOD, 60 ng input, 18-50 variants, baseline threshold: 0.008% AF | 80 | 0.008 | 0.008% / 0.0001 = 80 ppm | Not published | 18-50 variants; 10-60 ng cfDNA | peer-reviewed analytical validation (Invitae authors) | Not named in A58454. A58454 |
|
| Invitae Personalized Cancer Monitoring (PCM) | LOD, 10 ng input, 18 variants, monitoring threshold: 0.05% AF | 500 | 0.05 | 0.05% / 0.0001 = 500 ppm | |||||||
| FoundationOne Tracker | Foundation Medicine | tumor-informed (from tissue CGP results); Personalized plasma assay from FoundationOne tissue CGP alterations | Analytical sensitivity (not an LOD95 in ppm): >97.3% at >=5 mean tumor molecules/mL (2 monitorable alterations) | not convertible | not convertible | Not convertible (molecules/mL) | Not published | Depends on tissue CGP report | peer-reviewed analytical validation | Not named in A58454. A58454 |
|
NeXT Personal
Personalis; U.S. commercialization with Tempus
tumor-informed; Tumor + matched-normal WGS, personalized panel sequenced in plasma
Detection threshold (mean): 1.67 PPM
ppm: 1.67
VAF or TF %: 0.000167
1.67 ppm x 0.0001 = 0.000167%
LOD95: 3.45 PPM
ppm: 3.45
VAF or TF %: 0.000345
3.45 ppm x 0.0001 = 0.000345%
- LOQ / reporting floor
- Linearity 0.8 to 300,000 PPM (not stated as an LOQ)
- Variants / input
- Up to ~1,800 somatic variants
- Evidence
- peer-reviewed analytical validation (all authors Personalis employees)
- Medicare (A58454, R20)
- Named in A58454: neoadjuvant breast; recurrence/relapse with personal history of cancer for NSCLC and advanced breast; ICI-response monitoring in stage IV solid tumors. A58454
- Source(s), checked
- Northcott et al., Oncotarget 2024, PMID 38484152 (checked 2026-11-17)
Signatera (exome-based, bespoke multiplex PCR)
Natera
tumor-informed; Tumor + matched-normal WES, 16 clonal variants by multiplex PCR, ultra-deep sequencing
Limit of detection: not independently published
ppm: not independently published
VAF or TF %: not independently published
not independently published
- LOQ / reporting floor
- not independently published
- Variants / input
- not independently published
- Evidence
- not independently published
- Medicare (A58454, R20)
- Named in A58454: advanced colorectal; muscle-invasive bladder and ovarian; neoadjuvant breast; NSCLC and advanced breast recurrence; ICI-response monitoring (advanced solid tumors). A58454
- Source(s), checked
Signatera Genome
Natera
tumor-informed; WGS-based design
Limit of detection: not independently published
ppm: not independently published
VAF or TF %: not independently published
not independently published
- LOQ / reporting floor
- Not published
- Variants / input
- not independently published
- Evidence
- not independently published
- Medicare (A58454, R20)
- Not named separately in A58454 (Signatera listings do not specify Genome). A58454
- Source(s), checked
RaDaR ST
NeoGenomics
tumor-informed; Tumor sequencing to select variants; patient-specific amplicon panel
Limit of detection: not independently published
ppm: not independently published
VAF or TF %: not independently published
not independently published
- LOQ / reporting floor
- not independently published
- Variants / input
- Up to 48 tumor-specific variants (Gale 2022, original RaDaR)
- Evidence
- variant count is peer-reviewed; the limit of detection is not independently published
- Medicare (A58454, R20)
- Named in A58454: HPV-negative HNSCC; advanced breast recurrence; ICI-response monitoring in stage IV solid tumors (added in R20, effective 4/9/2026). A58454
- Source(s), checked
- Gale et al., Ann Oncol 2022, PMID 35306155 (up to 48 amplicons) (checked 2026-11-17)
Haystack MRD
Quest Diagnostics (Haystack Oncology)
tumor-informed; Tracks patient-specific somatic mutations with duplex error correction
LOD95 (peer-reviewed): 0.063 mean ctDNA molecules/mL
ppm: not convertible
VAF or TF %: not convertible
Not convertible: molecules per mL of plasma depend on total cfDNA per mL
- LOQ / reporting floor
- Analytical measurement range 0.25 to 1000 mean ctDNA molecules/mL
- Variants / input
- Not stated in abstract
- Evidence
- peer-reviewed analytical + clinical validation (Quest/Haystack authors)
- Medicare (A58454, R20)
- Not named in A58454. A58454
- Source(s), checked
- Clark et al., J Mol Diagn 2026, PMID 42624249 (checked 2026-11-17)
Oncodetect (next-generation, WGS + MAESTRO)
Exact Sciences
tumor-informed; WGS-based design with MAESTRO enrichment
Limit of detection: not independently published
ppm: not independently published
VAF or TF %: not independently published
not independently published
- LOQ / reporting floor
- Not published
- Variants / input
- not independently published
- Evidence
- not independently published
- Medicare (A58454, R20)
- Named in A58454 as Oncodetect for advanced colorectal cancer. Whether that listing covers a later version is not stated in the Medicare article. A58454
- Source(s), checked
Pathlight
SAGA Diagnostics
tumor-informed; Tumor WGS to find structural variants; personalized multiplex digital PCR
LoD95 at 70 ng cfDNA input: 0.00052% (paper rounds to 5 ppm)
ppm: 5.2
VAF or TF %: 0.00052
0.00052% / 0.0001 = 5.2 ppm
LoD95 at 300 ng input: 0.00011% (1.1 ppm)
ppm: 1.1
VAF or TF %: 0.00011
0.00011% / 0.0001 = 1.1 ppm
- LOQ / reporting floor
- Not published
- Variants / input
- Up to 16 SVs per tumor (median 14, range 4-16 in the study); LoD95 at 70 ng and 300 ng input
- Evidence
- peer-reviewed (cell-line dilution, probit)
- Medicare (A58454, R20)
- Named in A58454: advanced breast recurrence/relapse with personal history of cancer. A58454
- Source(s), checked
- Elliott et al., Clin Cancer Res 2025, PMID 39785866, PMC11994999 (checked 2026-11-17)
Precise MRD
Myriad Genetics
tumor-informed; WGS-based personalized panel
Limit of detection: not independently published
ppm: not independently published
VAF or TF %: not independently published
not independently published
- LOQ / reporting floor
- Not published
- Variants / input
- not independently published
- Evidence
- not independently published
- Medicare (A58454, R20)
- Not named in A58454. A58454
- Source(s), checked
Invitae Personalized Cancer Monitoring (PCM)
Invitae (select assets acquired by Labcorp, 2024)
tumor-informed; Tumor + germline WES; patient-specific panel
LOD, 60 ng input, 18-50 variants, baseline threshold: 0.008% AF
ppm: 80
VAF or TF %: 0.008
0.008% / 0.0001 = 80 ppm
LOD, 10 ng input, 18 variants, monitoring threshold: 0.05% AF
ppm: 500
VAF or TF %: 0.05
0.05% / 0.0001 = 500 ppm
- LOQ / reporting floor
- Not published
- Variants / input
- 18-50 variants; 10-60 ng cfDNA
- Evidence
- peer-reviewed analytical validation (Invitae authors)
- Medicare (A58454, R20)
- Not named in A58454. A58454
- Source(s), checked
- Zhao et al., Mol Diagn Ther 2023, PMID 37632661 (checked 2026-11-17)
FoundationOne Tracker
Foundation Medicine
tumor-informed (from tissue CGP results); Personalized plasma assay from FoundationOne tissue CGP alterations
Analytical sensitivity (not an LOD95 in ppm): >97.3% at >=5 mean tumor molecules/mL (2 monitorable alterations)
ppm: not convertible
VAF or TF %: not convertible
Not convertible (molecules/mL)
- LOQ / reporting floor
- Not published
- Variants / input
- Depends on tissue CGP report
- Evidence
- peer-reviewed analytical validation
- Medicare (A58454, R20)
- Not named in A58454. A58454
- Source(s), checked
- Zollinger et al., PLoS One 2024, PMID 38753705 (checked 2026-11-17)
Tumor-naive / tissue-free
| Assay | Vendor | Approach / method | LOD as stated | ppm | VAF or TF % | Conversion | LOQ / reporting floor | Variants / input | Evidence | Medicare (A58454, R20) | Source(s), checked |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Guardant Reveal | Guardant Health | tumor-naive (tissue-free); Plasma-only, methylation-based tumor fraction | LOD95 at 3-4 ng cfDNA (as cited in a peer-reviewed paper): 0.02% | 200 | 0.02 | 0.02% / 0.0001 = 200 ppm (tumor fraction) | Minimum reported tumor fraction 0.05% (500 ppm) in the lung assay, per the MGB methods section: July 2023 range 0.05%-8.7% with LOD 0.05%; December 2024 range 0.05%-10% with LOD lowered to 0.01%, minimum reported value still 0.05%. | Fixed methylation panel; 3-4 ng and 15 ng cfDNA inputs in LOD studies | peer-reviewed citation of an analytical abstract, plus a reporting floor from an independent cohort | Named in A58454: advanced colorectal cancer (progression, recurrence, relapse). A58454 | |
| Guardant Reveal | LOD95 at 15 ng cfDNA (as cited in a peer-reviewed paper): 0.005% | 50 | 0.005 | 0.005% / 0.0001 = 50 ppm (tumor fraction) | |||||||
| Northstar Response | BillionToOne | tumor-naive (tissue-free); treatment-response monitoring; Methylation panel | Limit of detection: not independently published | not independently published | not independently published | not independently published | Not published | not independently published | not independently published | Not named in A58454. A58454 | |
| NavDx | Naveris | virus-informed, tissue-free (HPV-driven cancers only); Tumor tissue-modified viral HPV DNA (types 16, 18, 31, 33, 35) by digital PCR | LOD range across HPV genotypes: 0-1.10 copies/uL | not convertible | not convertible | Not convertible (copies per microliter) | LOQ <1.20-4.11 copies/uL; LOB 0-0.32 copies/uL | 5 HPV genotypes | peer-reviewed (Naveris authors) | Named in A58454: HPV-driven oropharyngeal and anal squamous cell cancers (recurrence/relapse). A58454 |
|
Guardant Reveal
Guardant Health
tumor-naive (tissue-free); Plasma-only, methylation-based tumor fraction
LOD95 at 3-4 ng cfDNA (as cited in a peer-reviewed paper): 0.02%
ppm: 200
VAF or TF %: 0.02
0.02% / 0.0001 = 200 ppm (tumor fraction)
LOD95 at 15 ng cfDNA (as cited in a peer-reviewed paper): 0.005%
ppm: 50
VAF or TF %: 0.005
0.005% / 0.0001 = 50 ppm (tumor fraction)
- LOQ / reporting floor
- Minimum reported tumor fraction 0.05% (500 ppm) in the lung assay, per the MGB methods section: July 2023 range 0.05%-8.7% with LOD 0.05%; December 2024 range 0.05%-10% with LOD lowered to 0.01%, minimum reported value still 0.05%.
- Variants / input
- Fixed methylation panel; 3-4 ng and 15 ng cfDNA inputs in LOD studies
- Evidence
- peer-reviewed citation of an analytical abstract, plus a reporting floor from an independent cohort
- Medicare (A58454, R20)
- Named in A58454: advanced colorectal cancer (progression, recurrence, relapse). A58454
- Source(s), checked
Northstar Response
BillionToOne
tumor-naive (tissue-free); treatment-response monitoring; Methylation panel
Limit of detection: not independently published
ppm: not independently published
VAF or TF %: not independently published
not independently published
- LOQ / reporting floor
- Not published
- Variants / input
- not independently published
- Evidence
- not independently published
- Medicare (A58454, R20)
- Not named in A58454. A58454
- Source(s), checked
NavDx
Naveris
virus-informed, tissue-free (HPV-driven cancers only); Tumor tissue-modified viral HPV DNA (types 16, 18, 31, 33, 35) by digital PCR
LOD range across HPV genotypes: 0-1.10 copies/uL
ppm: not convertible
VAF or TF %: not convertible
Not convertible (copies per microliter)
- LOQ / reporting floor
- LOQ <1.20-4.11 copies/uL; LOB 0-0.32 copies/uL
- Variants / input
- 5 HPV genotypes
- Evidence
- peer-reviewed (Naveris authors)
- Medicare (A58454, R20)
- Named in A58454: HPV-driven oropharyngeal and anal squamous cell cancers (recurrence/relapse). A58454
- Source(s), checked
- Diagnostics 2023, PMID 36832208 (checked 2026-11-17)
Blood-cancer assays (reference only, different biology)
| Assay | Vendor | Approach / method | LOD as stated | ppm | VAF or TF % | Conversion | LOQ / reporting floor | Variants / input | Evidence | Medicare (A58454, R20) | Source(s), checked |
|---|---|---|---|---|---|---|---|---|---|---|---|
| clonoSEQ (blood cancers; reference only) | Adaptive Biotechnologies | tumor-informed immune-receptor sequencing (not solid-tumor ctDNA); Patient-specific Ig/TCR rearrangements | LoD: 1.903 malignant cells | not convertible | not convertible | Not convertible without stated DNA input (cells, not a fraction) | LoQ 2.390 malignant cells; LoB 0 | Depends on DNA input | peer-reviewed (Adaptive author) | Not in A58454 (solid-tumor article). A58454 |
|
| Foresight CLARITY (PhasED-Seq; lymphoma; reference only) | Foresight Diagnostics | tumor-informed phased variants; PhasED-Seq | LOD95 at 120 ng input: 0.7 parts per million | 0.7 | 7e-05 | 0.7 ppm x 0.0001 = 0.00007% | Not published | 120 ng input DNA | peer-reviewed (Foresight authors), B-cell malignancies | Not in A58454 (solid-tumor article). A58454 |
|
clonoSEQ (blood cancers; reference only)
Adaptive Biotechnologies
tumor-informed immune-receptor sequencing (not solid-tumor ctDNA); Patient-specific Ig/TCR rearrangements
LoD: 1.903 malignant cells
ppm: not convertible
VAF or TF %: not convertible
Not convertible without stated DNA input (cells, not a fraction)
- LOQ / reporting floor
- LoQ 2.390 malignant cells; LoB 0
- Variants / input
- Depends on DNA input
- Evidence
- peer-reviewed (Adaptive author)
- Medicare (A58454, R20)
- Not in A58454 (solid-tumor article). A58454
- Source(s), checked
- Ching et al., BMC Cancer 2020, PMID 32605647 (checked 2026-11-17)
Foresight CLARITY (PhasED-Seq; lymphoma; reference only)
Foresight Diagnostics
tumor-informed phased variants; PhasED-Seq
LOD95 at 120 ng input: 0.7 parts per million
ppm: 0.7
VAF or TF %: 7e-05
0.7 ppm x 0.0001 = 0.00007%
- LOQ / reporting floor
- Not published
- Variants / input
- 120 ng input DNA
- Evidence
- peer-reviewed (Foresight authors), B-cell malignancies
- Medicare (A58454, R20)
- Not in A58454 (solid-tumor article). A58454
- Source(s), checked
- Oncotarget 2025, PMID 40353795 (checked 2026-11-17)
Row notes
- NeXT Personal: Also called xM (NeXT Personal Dx). 1.67 PPM is the paper's mean detection threshold; LOD95 is 3.45 PPM.
- Signatera (exome-based, bespoke multiplex PCR): No peer-reviewed analytical-validation paper was found for this limit of detection.
- Signatera Genome: Cell-line dilution figures were vendor data on file. Not independently published.
- RaDaR ST: The 11 ppm LOD95 was vendor data on file and is not shown.
- Haystack MRD: The paper reports molecules per mL. A percent figure on the company site is not independently published and is not shown.
- Oncodetect (next-generation, WGS + MAESTRO): The stated limit of detection came from a company page and is not shown.
- Precise MRD: The stated limit of detection came from a company page and is not shown.
- Invitae Personalized Cancer Monitoring (PCM): Current commercial name/availability under Labcorp not re-verified today.
- Guardant Reveal: Tumor fraction, not variant allele fraction. A company-page limit of detection is not shown. The 0.05% floor is documented for the lung assay in the Mass General Brigham paper.
- Northstar Response: The stated limit of detection came from a company page and is not shown.
- clonoSEQ (blood cancers; reference only): Regulatory status beyond the peer-reviewed methods paper is not restated from a company site.
Mass General Brigham transient-positive study
Fluctuating Methylation-based ctDNA Detection in NSCLC Surveillance: Implications for Serial Monitoring and Specificity, Cho JM, et al. (Mass General Brigham / Dana-Farber), JTO Clinical and Research Reports, 2026 (Collection Dec 2026), PMID 43036776 (checked 2026-11-17). DOI.
Assay: Guardant Reveal (named in Methods; abstract says 'a commercially available methylation-based ctDNA test').
Design: Retrospective, single center; 85 patients after lung resection or SBRT for NSCLC; surveillance testing 2024-2025.
- 17 of 85 (20%) had at least one positive test
- 10 of 17 (59%) later tested negative with no recurrence at the time
- 11 of 17 (65%) were positive only at or near 0.05% tumor fraction, the minimum reported value, without radiographic recurrence; one patient had 3 serial low-level positives without recurrence
- 3 patients with tumor fractions above that level (>10%, 0.25%, 0.55%) all had recurrence; 1 more patient at 0.2% later tested negative and had no recurrence on imaging
- No recurrences in the ctDNA-negative group during follow-up
Authors' conclusion: Isolated low-level positivity may not warrant clinical action; results should be read as trends.
Limits: Retrospective, small, single center, short follow-up, no systematic comparison with mutation-based testing, only 3 SBRT patients.
Funding: DF/HCC Lung SPORE Career Enhancement award; no Guardant funding or disclosure found.
Context: Transient early positives are not unique to tissue-free tests: a tumor-informed NSCLC study (Gale 2022, RaDaR) found ctDNA 1-3 days after surgery in 25% of patients that was not associated with recurrence. Gale 2022.
Left out (could not verify a number today)
- Tempus xM (tumor-naive, CRC): No analytical LOD published (Nakamura CCR 2025 reports clinical performance only: landmark sensitivity 61.1%, specificity 87.9%; longitudinal 83.3%/89.5%). Do not apply NeXT Personal figures. https://pubmed.ncbi.nlm.nih.gov/39513962/ (checked 2026-11-17)
- Northstar Clear (tissue-free MRD): No limit of detection is independently published. (checked 2026-11-17)
- Guardant Reveal Ultra: 'LOD at one part per million or below' appears only in a Q3 2026 earnings-call transcript in the dossier; no live spec sheet or paper found. /workspace/dossiers/guardant-reveal/2026-11-06_q3_transcript_ultra.txt (checked 2026-11-17)
- Veracyte TrueMRD: No commercial LOD found in a live primary source (research MRDetect paper only). Medicare-listed for MIBC. https://www.cms.gov/medicare-coverage-database/view/article.aspx?articleid=58454 (checked 2026-11-17)
- Labcorp Plasma Detect: Only a conference abstract (2024) was found earlier; not re-verified. (checked 2026-11-17)
- Precise MRD AACR 2026 abstract 2598 (<5 ppm genome equivalents): AACR page timed out / returned 403 today; vendor 1.45 ppm kept instead, labeled vendor. https://doi.org/10.1158/1538-7445.AM2026-2598 (checked 2026-11-17)
Medicare source
CMS MolDX billing article A58454, revision R20, revision effective 10/01/2026, revision ending N/A (checked 2026-11-17). Coverage is indication-specific; a listing means the test met MolDX criteria for the named uses only.
Fact-only. Tempus-marketed assays appear like any other vendor's. No ranking.